Ramaswamy-backed pain drug firm to go public via reverse merger
A California-based biotech developing a chronic pain treatment that has been available in Italy for years but lacks US approval is pursuing a reverse merger to list publicly. The company, co-founded by Vivek Ramaswamy, is taking advantage of the growing trend of such deals. The drug's regulatory status in the US remains a key hurdle.
Reverse mergers have become an increasingly common route for biotech firms seeking public capital without the lengthy process of a traditional IPO. This California-based company, co-founded by Vivek Ramaswamy, is pursuing that path while developing a chronic pain treatment already sold in Italy for years. The drug’s lack of U.S. approval remains a central obstacle, as regulatory scrutiny of pain medications—especially those with opioid-related profiles—has tightened. The move reflects a broader pattern where early-stage drug developers turn to faster listing mechanisms to fund clinical trials and regulatory submissions, even when their lead product faces an uncertain path to market in the United States.
If the reverse merger succeeds, the company could gain access to public markets and investor funding, potentially accelerating its U.S. regulatory efforts. Chronic pain patients may see a new treatment option if approval is eventually granted, but the drug’s long-standing absence from the U.S. market suggests significant safety or efficacy questions remain. Investors could face volatility given the regulatory uncertainty, while the wider biotech sector may view this as another example of how reverse mergers enable high-risk drug development to proceed outside traditional IPO scrutiny.